All In Biotech

Free tool

FAERS Monitor: Ganirelix Acetate

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021057 or its brand name (Ganirelix Acetate, Ganirelix Acetate). Reports on generic versions are filed under their own applications.

Reports

719

Serious

327

45% of reports

Hospitalization

245

Death reported

4

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • ovarian hyperstimulation syndrome225
  • needle issue48
  • ascites44
  • nausea44
  • no adverse event40
  • poor quality device used40
  • headache36
  • injection site pain34
  • drug ineffective31
  • dyspnoea29
  • fatigue29
  • product quality issue28
  • abdominal distension27
  • abdominal pain27
  • maternal exposure during pregnancy22

Reports by year received

View as table
YearReports
20111
20121
201320
201448
20152
20168
20174
201824
201951
202031
202145
2022114
202358
2024101
202568
2026143

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,440 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
ovarian hyperstimulation syndromeSignal2253125.42781.9632,239
poor quality device usedSignal40117.186.64,473
needle issueSignal4848.336.72,176
ascitesSignal4443.832.91,799
abdominal distensionSignal277.65.2148
maternal exposure during pregnancySignal227.24.8112
no adverse eventSignal406.54.8181
product quality issueSignal286.04.2113
abdominal painSignal273.42.344
injection site painSignal343.22.351
headache361.71.210
nausea441.61.210
dyspnoea291.51.04
fatigue291.10.80
drug ineffective310.70.54

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.